Viking Therapeutics (VKTX) Is Up 5.6% After Expanding At-The-Market Offerings And Shelf Registration - Has The Bull Case Changed?

• In July 2026, Viking Therapeutics reported a second-quarter net loss of US$128.02 million and a six-month net loss of US$286.35 million, while simultaneously raising about US$159.59 million through multiple at-the-market follow-on common stock offerings.
• On the same day, the company also filed a US$500 million at-the-market follow-on offering and an omnibus shelf registration covering a wide range of securities, signaling a deliberate move to expand its financing options and balance sheet flexibility as losses increase.
• Next, we’ll examine how this expanded at-the-market fundraising capacity and shelf registration affect Viking Therapeutics’ investment narrative and risk profile.

Invest in the nuclear renaissance through our list of 89 elite nuclear energy infrastructure plays powering the global AI revolution.

Viking Therapeutics Investment Narrative Recap

To own Viking Therapeutics today, you need to believe its VK2735 obesity franchise can eventually justify ongoing heavy losses and dilution risk. The July 2026 results, with a larger net loss and new US$500.0 million at the market capacity, do not change the near term catalyst, which still centers on upcoming VANQUISH Phase III and maintenance data. They do, however, keep financing risk and potential future dilution squarely in focus as the key near term concern.

The most relevant announcement here is Viking’s filing of a broad omnibus shelf registration alongside the expanded US$500.0 million at the market program. Together with the US$159.59 million already raised, this gives the company considerable flexibility to fund its late stage VK2735 trials and broader pipeline while losses remain high. For investors watching the VANQUISH readouts, it directly ties the clinical catalysts to an ongoing risk of incremental equity issuance.

But while the clinical story may be compelling, the combination of rising net losses and expanded equity capacity is something investors should be aware of as they consider...

Read the full narrative on Viking Therapeutics (it's free!)

Viking Therapeutics’ narrative projects $118.5 million in revenue and $12.9 million in earnings by 2029. This assumes an earnings increase of about $372.5 million from current earnings of -$359.6 million.

Uncover how Viking Therapeutics' forecasts yield a $92.72 fair value, a 169% upside to its current price.

Exploring Other Perspectives

Before this latest loss and fundraising, the most optimistic analysts were modeling about US$497.5 million of revenue by 2029, which contrasts sharply with today’s larger losses and fresh US$500.0 million at the market capacity you now need to factor in.

Explore 9 other fair value estimates on Viking Therapeutics - why the stock might be worth less than half the current price!

The Verdict Is Yours

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Viking Therapeutics research is our analysis highlighting 3 important warning signs that could impact your investment decision.
• Our free Viking Therapeutics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Viking Therapeutics' overall financial health at a glance.

Ready For A Different Approach?

Every day counts. These free picks are already gaining attention. See them before the crowd does:

• AI is about to change healthcare. These 43 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• The future of work is here. Discover the 37 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
• Uncover the next big thing with 20 elite penny stocks that balance risk and reward.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com